Skip to main content
SpringerLink
Log in

The Role for Radical Prostatectomy in Advanced Prostate Cancer

  • Chapter
  • First Online:
Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1456 Accesses

Abstract

Radical prostatectomy can be an effective treatment in the management of high-risk or locally advanced prostate cancer. Radical prostatectomy provides accurate pathologic grading and staging and when used alone or as part of multimodal treatment can result in acceptable long-term local control and prostate cancer survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cooperberg MR, Lubeck DP, Mehta SS, et al. CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170(6 Pt 2):S21–5. Erratum in J Urol. 2004;171(2 Pt 1):811.

    Google Scholar 

  2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19): 1977–84.

    Article  PubMed  CAS  Google Scholar 

  3. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9): 1508–13.

    Article  PubMed  Google Scholar 

  4. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  5. Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D’Amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179(4):1354–60.

    Article  PubMed  Google Scholar 

  6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.

    Article  PubMed  CAS  Google Scholar 

  7. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300–5.

    Article  PubMed  Google Scholar 

  8. Meng MV, Elkin EP, Latini DM, et al. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 2005;173(5):1557–61.

    Article  PubMed  Google Scholar 

  9. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660): 301–8.

    Article  PubMed  CAS  Google Scholar 

  10. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53:950–9.

    Article  PubMed  Google Scholar 

  11. Messing EM, Manola J, Yao J, et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–9.

    Article  PubMed  CAS  Google Scholar 

  12. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27): 4448–56.

    Article  PubMed  CAS  Google Scholar 

  13. Manoharan M, Bird VG, Kim SS, et al. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int. 2003;92(6): 539–44.

    Article  PubMed  CAS  Google Scholar 

  14. Boorjian SA, Karnes RJ, Crispen PL, et al. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009;181(1):95–104.

    Article  PubMed  Google Scholar 

  15. Kane CJ, Presti Jr JC, Amling CL, et al. SEARCH Database Study Group. Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007;177(1):113–7.

    Article  PubMed  Google Scholar 

  16. Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol. 2008;26(24):3930–6.

    Article  PubMed  Google Scholar 

  17. Karnes RJ, Cheville JC, Ida CM, et al. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010;70(22): 8994–9002.

    Article  PubMed  CAS  Google Scholar 

  18. Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002;167(1):117–22. Erratum in J Urol. 2004;171(2 Pt 1):811.

    Google Scholar 

  19. Sciarra A, Gentile V, Voria G, et al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8–10. Urol Int. 2003;70(3):186–94.

    Article  PubMed  Google Scholar 

  20. Hurwitz MD, Schultz D, Richie JP, et al. Radical prostatectomy for high-grade prostate cancer. Urology. 2006;68(2):367–70.

    Article  PubMed  Google Scholar 

  21. Boorjian SA, Karnes RJ, Rangel LJ, et al. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8–10 cancers. BJU Int. 2008;101(3): 299–304.

    Article  PubMed  Google Scholar 

  22. Aihara M, Lebovitz RM, Wheeler TM, et al. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994;151(6):1558–64.

    PubMed  CAS  Google Scholar 

  23. Tollefson M, Blute M, Rangel L, et al. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010;105(10):1381–5.

    Article  PubMed  Google Scholar 

  24. Do TM, Parker RG, Smith RB, et al. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology. 2001;57(6):1121–6.

    Article  PubMed  CAS  Google Scholar 

  25. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–6.

    Article  PubMed  CAS  Google Scholar 

  26. Zincke H, Bergstralh EJ, Larson-Keller JJ, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer. 1992;70(1 Suppl):311–23.

    Article  PubMed  CAS  Google Scholar 

  27. Inman BA, Davies JD, Rangel LJ, et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥50 ng/mL. Cancer. 2008;113(7):1544–51.

    Article  PubMed  Google Scholar 

  28. D’Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate ­cancer. J Clin Oncol. 1999;17(1):168–72.

    PubMed  Google Scholar 

  29. Zincke H, Lau W, Bergstralh E, et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol. 2001;166(6):2208–15.

    Article  PubMed  CAS  Google Scholar 

  30. See W, Iversen P, Wirth M, et al. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol. 2003;44(5):512–7.

    Article  PubMed  CAS  Google Scholar 

  31. Bolla M, van Poppel H, Collette L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.

    Article  PubMed  Google Scholar 

  32. Weigel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen. J Clin Oncol. 2009;27:2924–30.

    Article  Google Scholar 

  33. Thompson IM, Tangen CM, Pardelelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–62.

    Article  PubMed  Google Scholar 

  34. Zagars GK, von Eschenbach AC, Ayala AG, et al. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 1991;68(11):2370–7.

    Article  PubMed  CAS  Google Scholar 

  35. Crook JM, Perry GA, Robertson S, et al. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology. 1995;45(4): 624–31.

    Article  PubMed  CAS  Google Scholar 

  36. Coen JJ, Zietman AL, Thakral H, et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20(15):3199–205.

    Article  PubMed  Google Scholar 

  37. D’Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21(11):2163–72.

    Article  PubMed  Google Scholar 

  38. Akakura K, Isaka S, Akimoto S, et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology. 1999;54(2):313–8.

    Article  PubMed  CAS  Google Scholar 

  39. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349(9056):906–10.

    Article  PubMed  CAS  Google Scholar 

  40. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6): 751–6.

    Article  PubMed  Google Scholar 

  41. Meltzer D, Egleston B, Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health. 2001;91(1):126–8.

    Article  PubMed  CAS  Google Scholar 

  42. Vallett BS. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Del Med J. 1944;16:19–20.

    Google Scholar 

  43. Tomlinson RL, Currie DP, Boyce WH. Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol. 1977;117(1):85–7.

    PubMed  CAS  Google Scholar 

  44. Anast JW, Andriole GL, Grubb RL. Managing the local complications of locally advanced prostate cancer. Curr Urol Rep. 2007;8(3):211–6.

    Article  PubMed  Google Scholar 

  45. Bruchovsky N, Brown EM, Coppin CM, et al. The endocrinology and treatment of prostate tumor progression. Prog Clin Biol Res. 1987;239:347–87.

    PubMed  CAS  Google Scholar 

  46. Canby-Hagiono ED, Swanson GP, Crawford ED, et al. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep. 2005;6:183–9.

    Article  Google Scholar 

  47. Carver BS, Bianco Jr FJ, Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176(2):564–8.

    Article  PubMed  Google Scholar 

  48. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.

    Article  PubMed  Google Scholar 

  49. Tsai HK, D’Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24.

    Article  PubMed  Google Scholar 

  50. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–504.

    Article  PubMed  CAS  Google Scholar 

  51. Freedland SJ, Partin AW, Humphreys EB, et al. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007;109(7):1273–8.

    Article  PubMed  Google Scholar 

  52. NCCN Clinical practice guidelines in oncology: prostate cancer. National Comprehensive Cancer Network. v.2.2010. Available from http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    R. Jeffrey Karnes & Michael L. Blute

Authors
  1. R. Jeffrey Karnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael L. Blute
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Jeffrey Karnes .

Editor information

Editors and Affiliations

  1. , Glickman Urological and Kidney, Cleveland Clinic, 9500 Euclid Ave, Cleveland, 44195, Ohio, USA

    Eric A. Klein

  2. Cleveland Clinic, Cleveland Clinic Lerner College of Medic, Department of Regional Urology, at Case Western Reserve, Cleveland, 44195, Ohio, USA

    J. Stephen Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Karnes, R.J., Blute, M.L. (2012). The Role for Radical Prostatectomy in Advanced Prostate Cancer. In: Klein, E., Jones, J. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-259-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-259-9_17

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-258-2

  • Online ISBN: 978-1-60761-259-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation